US panel review for Genentech's Avastin in brain cancer
This article was originally published in Scrip
Executive Summary
The US FDA's oncologic drugs advisory committee will meet on March 31st to discuss Genentech's sBLA for monotherapy use of the anti-VEGF monoclonal antibody Avastin (bevacizumab) in previously treated glioblastoma.